Largos supervivientes y terapias dirigidas en melanoma avanzado - page 38

Nuevos ensayos iMAPK ± inmunot.

Vemurafenib

Cobimetinib

Atezolizumab*

Encorafenib*

Binimetinib*

Nivolumab

Dabrafenib

Trametinib

PDR001*

Pembrolizumab

Nivolumab +

ipilimumab

Durvalumab*

*Productoexperimental, noautorizado

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,28,29,30,31,32,33,34,35,36,37 39,40,41,42,43,44,45,46